ThisCART-19

N/A

Report date: 2024/07/02 16:38:18

Base Information

Drug NameThisCART-19
Drug Alias NameThisCART-19ThisCART19BThisCART19CThisCART-19-AThisCART19A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAnemia, Hemolytic, AutoimmuneLymphoma, AIDS-RelatedLymphoma, B-Cell +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesFundamenta Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFundamenta Therapeutics LtdZhengzhou UniversityZhejiang University
Inactive CompaniesThe First Affiliated Hospital Of Zhejiang University School Of Medicine
Active IndicationsAnemia, Hemolytic, AutoimmuneLymphoma, B-CellLymphoma, Non-Hodgkin +[7] 
Inactive IndicationsLymphoma, AIDS-RelatedLeukemia, Lymphoid

Other Information

ATC CodeN/A
Related LinksN/A